

# Carmine Dario Vizza

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/4090751/publications.pdf>

Version: 2024-02-01

181  
papers

13,556  
citations

50170

46  
h-index

22102

113  
g-index

192  
all docs

192  
docs citations

192  
times ranked

9899  
citing authors

#	ARTICLE	IF	CITATIONS
1	2019 ESC Guidelines for the diagnosis and management of acute pulmonary embolism developed in collaboration with the European Respiratory Society (ERS). <i>European Heart Journal</i> , 2020, 41, 543-603.	1.0	2,426
2	Macitentan and Morbidity and Mortality in Pulmonary Arterial Hypertension. <i>New England Journal of Medicine</i> , 2013, 369, 809-818.	13.9	1,168
3	Riociguat for the Treatment of Pulmonary Arterial Hypertension. <i>New England Journal of Medicine</i> , 2013, 369, 330-340.	13.9	1,120
4	Initial Use of Ambrisentan plus Tadalafil in Pulmonary Arterial Hypertension. <i>New England Journal of Medicine</i> , 2015, 373, 834-844.	13.9	906
5	2019 ESC Guidelines for the diagnosis and management of acute pulmonary embolism developed in collaboration with the European Respiratory Society (ERS). <i>European Respiratory Journal</i> , 2019, 54, 1901647.	3.1	806
6	Effects of beraprost sodium, an oral prostacyclin analogue, in patients with pulmonary arterial hypertension: a randomized, double-blind, placebo-controlled trial. <i>Journal of the American College of Cardiology</i> , 2002, 39, 1496-1502.	1.2	584
7	Mortality in pulmonary arterial hypertension: prediction by the 2015 European pulmonary hypertension guidelines risk stratification model. <i>European Respiratory Journal</i> , 2017, 50, 1700740.	3.1	489
8	Elderly patients diagnosed with idiopathic pulmonary arterial hypertension: Results from the COMPERA registry. <i>International Journal of Cardiology</i> , 2013, 168, 871-880.	0.8	357
9	Anticoagulation and Survival in Pulmonary Arterial Hypertension. <i>Circulation</i> , 2014, 129, 57-65.	1.6	317
10	Right and Left Ventricular Dysfunction in Patients With Severe Pulmonary Disease. <i>Chest</i> , 1998, 113, 576-583.	0.4	290
11	Pre-Capillary, Combined, and Post-Capillary Pulmonary Hypertension. <i>Journal of the American College of Cardiology</i> , 2016, 68, 368-378.	1.2	244
12	An official European Respiratory Society statement: pulmonary haemodynamics during exercise. <i>European Respiratory Journal</i> , 2017, 50, 1700578.	3.1	222
13	Pregnancy outcomes in pulmonary arterial hypertension in the modern management era. <i>European Respiratory Journal</i> , 2012, 40, 881-885.	3.1	221
14	Prostanoid therapy for pulmonary arterial hypertension. <i>Journal of the American College of Cardiology</i> , 2004, 43, S56-S61.	1.2	184
15	Chronic Inhibition of cGMP Phosphodiesterase 5A Improves Diabetic Cardiomyopathy. <i>Circulation</i> , 2012, 125, 2323-2333.	1.6	171
16	Changes in Right Ventricular Function Measured by Cardiac Magnetic Resonance Imaging in Patients Receiving Pulmonary Arterial Hypertension-Targeted Therapy. <i>Circulation: Cardiovascular Imaging</i> , 2014, 7, 107-114.	1.3	139
17	Outcomes of noncardiac, nonobstetric surgery in patients with PAH: an international prospective survey. <i>European Respiratory Journal</i> , 2013, 41, 1302-1307.	3.1	131
18	COMPERA 2.0: a refined four-stratum risk assessment model for pulmonary arterial hypertension. <i>European Respiratory Journal</i> , 2022, 60, 2102311.	3.1	124

#	ARTICLE	IF	CITATIONS
19	RESPITE: switching to riociguat in pulmonary arterial hypertension patients with inadequate response to phosphodiesterase-5 inhibitors. <i>European Respiratory Journal</i> , 2017, 50, 1602425.	3.1	113
20	Riociguat for the treatment of pulmonary arterial hypertension associated with connective tissue disease: results from PATENT-1 and PATENT-2. <i>Annals of the Rheumatic Diseases</i> , 2017, 76, 422-426.	0.5	108
21	Idiopathic pulmonary arterial hypertension phenotypes determined by cluster analysis from the COMPERA registry. <i>Journal of Heart and Lung Transplantation</i> , 2020, 39, 1435-1444.	0.3	104
22	Long-term safety and efficacy of imatinib in pulmonary arterial hypertension. <i>Journal of Heart and Lung Transplantation</i> , 2015, 34, 1366-1375.	0.3	103
23	Risk Reduction and Right Heart Reverse Remodeling by Upfront Triple Combination Therapy in Pulmonary Arterial Hypertension. <i>Chest</i> , 2020, 157, 376-383.	0.4	97
24	Sildenafil in severe pulmonary hypertension associated with chronic obstructive pulmonary disease: A randomized controlled multicenter clinical trial. <i>Journal of Heart and Lung Transplantation</i> , 2017, 36, 166-174.	0.3	89
25	Combination Therapy with Oral Treprostinil for Pulmonary Arterial Hypertension. A Double-Blind Placebo-controlled Clinical Trial. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2020, 201, 707-717.	2.5	89
26	Locoregional versus general anesthesia in carotid surgery: Is there an impact on perioperative myocardial ischemia? Results of a prospective monocentric randomized trial. <i>Journal of Vascular Surgery</i> , 1999, 30, 131-138.	0.6	87
27	Outcome of Patients with Cystic Fibrosis Awaiting Lung Transplantation. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2000, 162, 819-825.	2.5	86
28	Switching to riociguat versus maintenance therapy with phosphodiesterase-5 inhibitors in patients with pulmonary arterial hypertension (REPLACE): a multicentre, open-label, randomised controlled trial. <i>Lancet Respiratory Medicine</i> , 2021, 9, 573-584.	5.2	85
29	Right Intraventricular Dyssynchrony in Idiopathic, Heritable, and Anorexigen-Induced Pulmonary Arterial Hypertension. <i>JACC: Cardiovascular Imaging</i> , 2015, 8, 642-652.	2.3	83
30	Pulmonary Hypertension in Patients with Chronic Fibrosing Idiopathic Interstitial Pneumonias. <i>PLoS ONE</i> , 2015, 10, e0141911.	1.1	80
31	Long term effects of bosentan treatment in adult patients with pulmonary arterial hypertension related to congenital heart disease (Eisenmenger physiology): safety, tolerability, clinical, and haemodynamic effect. <i>Heart</i> , 2007, 93, 621-625.	1.2	75
32	Acute hemodynamic effects of inhaled nitric oxide, dobutamine and a combination of the two in patients with mild to moderate secondary pulmonary hypertension. <i>Critical Care</i> , 2001, 5, 355.	2.5	67
33	Systemic sclerosis patients with and without pulmonary arterial hypertension: a nailfold capillaroscopy study. <i>Rheumatology</i> , 2013, 52, 1525-1528.	0.9	67
34	Treatment of pulmonary hypertension in patients undergoing cardiac surgery with cardiopulmonary bypass: a randomized, prospective, double-blind study. <i>Journal of Cardiovascular Medicine</i> , 2006, 7, 119-123.	0.6	66
35	Right ventricular remodeling in idiopathic pulmonary arterial hypertension: adaptive versus maladaptive morphology. <i>Journal of Heart and Lung Transplantation</i> , 2015, 34, 395-403.	0.3	66
36	Transesophageal dipyrindamole echocardiography for diagnosis of coronary artery disease. <i>Journal of the American College of Cardiology</i> , 1992, 19, 765-770.	1.2	62

#	ARTICLE	IF	CITATIONS
37	Acute Hemodynamic Effects of Single-Dose Sildenafil When Added to Established Bosentan Therapy in Patients With Pulmonary Arterial Hypertension: Results of the COMPASS Study. <i>Journal of Clinical Pharmacology</i> , 2009, 49, 1343-1352.	1.0	57
38	Temporal trends in pulmonary arterial hypertension: results from the COMPERA registry. <i>European Respiratory Journal</i> , 2022, 59, 2102024.	3.1	57
39	Phenotyping of idiopathic pulmonary arterial hypertension: a registry analysis. <i>Lancet Respiratory Medicine</i> , 2022, 10, 937-948.	5.2	57
40	Therapy for pulmonary arterial hypertension due to congenital heart disease and Down's syndrome. <i>International Journal of Cardiology</i> , 2013, 164, 323-326.	0.8	55
41	Pulmonary Hypertension in Patients With COPD. <i>Chest</i> , 2021, 160, 678-689.	0.4	55
42	Right ventricular dyssynchrony in idiopathic pulmonary arterial hypertension: Determinants and impact on pump function. <i>Journal of Heart and Lung Transplantation</i> , 2015, 34, 381-389.	0.3	54
43	Echocardiography Combined With Cardiopulmonary Exercise Testing for the Prediction of Outcome in Idiopathic Pulmonary Arterial Hypertension. <i>Chest</i> , 2016, 150, 1313-1322.	0.4	51
44	Pulmonary hemodynamics contribute to indicate priority for lung transplantation in patients with cystic fibrosis. <i>Journal of Thoracic and Cardiovascular Surgery</i> , 2000, 119, 682-689.	0.4	50
45	Long term treatment of pulmonary arterial hypertension with beraprost, an oral prostacyclin analogue. <i>British Heart Journal</i> , 2001, 86, 661-665.	2.2	50
46	Prognostic factors in severe pulmonary hypertension patients who need parenteral prostanoid therapy: The impact of late referral. <i>Journal of Heart and Lung Transplantation</i> , 2012, 31, 364-372.	0.3	50
47	Circulating biomarkers in pulmonary arterial hypertension: Update and future direction. <i>Journal of Heart and Lung Transplantation</i> , 2015, 34, 282-305.	0.3	49
48	Influence of various therapeutic strategies on right ventricular morphology, function and hemodynamics in pulmonary arterial hypertension. <i>Journal of Heart and Lung Transplantation</i> , 2018, 37, 365-375.	0.3	49
49	Prognostic relevance of right heart reverse remodeling in idiopathic pulmonary arterial hypertension. <i>Journal of Heart and Lung Transplantation</i> , 2018, 37, 195-205.	0.3	46
50	Assessment of severity of coronary narrowings by quantitative exercise echocardiography and comparison with quantitative arteriography. <i>American Journal of Cardiology</i> , 1991, 67, 1201-1207.	0.7	41
51	Tissue-Type Plasminogen Activator Therapy Versus Primary Coronary Angioplasty: Impact on Myocardial Tissue Perfusion and Regional Function 1 Month After Uncomplicated Myocardial Infarction. <i>Journal of the American College of Cardiology</i> , 1998, 31, 338-343.	1.2	41
52	Risk Reduction and Hemodynamics with Initial Combination Therapy in Pulmonary Arterial Hypertension. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2021, 203, 484-492.	2.5	41
53	The importance of right ventricular evaluation in risk assessment and therapeutic strategies: Raising the bar in pulmonary arterial hypertension. <i>International Journal of Cardiology</i> , 2020, 301, 183-189.	0.8	40
54	Reconstruction of the pulmonary artery by a conduit of autologous pericardium. <i>Journal of Thoracic and Cardiovascular Surgery</i> , 1995, 110, 867-868.	0.4	38

#	ARTICLE	IF	CITATIONS
55	Comparative Effects of Irbesartan Versus Amlodipine on Left Ventricular Mass Index in Hypertensive Patients with Left Ventricular Hypertrophy. <i>Journal of Cardiovascular Pharmacology</i> , 2003, 42, 622-628.	0.8	37
56	Right ventricular dyssynchrony and exercise capacity in idiopathic pulmonary arterial hypertension. <i>European Respiratory Journal</i> , 2017, 49, 1601419.	3.1	37
57	Pulmonary Arterial Dilatation in Pulmonary Hypertension: Prevalence and Prognostic Relevance. <i>Cardiology</i> , 2012, 121, 76-82.	0.6	36
58	Preoperative Evaluation of Patients Undergoing Lung Resection Surgery: Defining the Role of the Anesthesiologist on a Multidisciplinary Team. <i>Journal of Cardiothoracic and Vascular Anesthesia</i> , 2016, 30, 530-538.	0.6	35
59	Pathophysiological adaptations to walking and cycling in primary pulmonary hypertension. <i>European Journal of Applied Physiology</i> , 2008, 102, 417-424.	1.2	32
60	Prognostic relevance of pulmonary arterial compliance after therapy initiation or escalation in patients with pulmonary arterial hypertension. <i>International Journal of Cardiology</i> , 2017, 230, 53-58.	0.8	32
61	Sildenafil dosed concomitantly with bosentan for adult pulmonary arterial hypertension in a randomized controlled trial. <i>BMC Cardiovascular Disorders</i> , 2017, 17, 239.	0.7	32
62	The added value of cardiopulmonary exercise testing in the follow-up of pulmonary arterial hypertension. <i>Journal of Heart and Lung Transplantation</i> , 2019, 38, 306-314.	0.3	32
63	Usefulness of Tricuspid Annular Velocity in Identifying Global RV Dysfunction in Patients with Primary Pulmonary Hypertension: A Comparison with 3D Echo-derived Right Ventricular Ejection Fraction. <i>Echocardiography</i> , 2008, 25, 289-293.	0.3	31
64	Clinical implications of idiopathic pulmonary arterial hypertension phenotypes defined by cluster analysis. <i>Journal of Heart and Lung Transplantation</i> , 2020, 39, 310-320.	0.3	31
65	Usefulness of the dipyridamole-Doppler test for diagnosis of coronary artery disease. <i>American Journal of Cardiology</i> , 1990, 65, 829-834.	0.7	30
66	Human Herpesvirus 8 and Pulmonary Hypertension. <i>Emerging Infectious Diseases</i> , 2005, 11, 1480-1482.	2.0	30
67	Right Ventricular Strain Curve Morphology and Outcome in Idiopathic Pulmonary Arterial Hypertension. <i>JACC: Cardiovascular Imaging</i> , 2021, 14, 162-172.	2.3	29
68	Occult lung cancer in patients with bullous emphysema. <i>Thorax</i> , 1997, 52, 289-290.	2.7	29
69	Right ventricular concentric hypertrophy and clinical worsening in idiopathic pulmonary arterial hypertension. <i>Journal of Heart and Lung Transplantation</i> , 2016, 35, 1321-1329.	0.3	28
70	Increased plasma levels of adrenomedullin, a vasoactive peptide, in patients with end-stage pulmonary disease. <i>Regulatory Peptides</i> , 2005, 124, 187-193.	1.9	27
71	Analysis of endothelin-1 and endothelin-1 receptor A gene polymorphisms in patients with pulmonary arterial hypertension. <i>Internal and Emergency Medicine</i> , 2012, 7, 425-430.	1.0	27
72	Haemodynamic effects of an acute vasodilator challenge in heart failure patients with reduced ejection fraction and different forms of postcapillary pulmonary hypertension. <i>European Journal of Heart Failure</i> , 2018, 20, 725-734.	2.9	27

#	ARTICLE	IF	CITATIONS
73	Aggressive Afterload Lowering to Improve the Right Ventricle: A New Target for Medical Therapy in Pulmonary Arterial Hypertension?. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2022, 205, 751-760.	2.5	27
74	HIV-related pulmonary hypertension. <i>Acta Cardiologica</i> , 2004, 59, 323-330.	0.3	26
75	Inhaled aerosolized prostacyclin and pulmonary hypertension during anesthesia for lung transplantation. <i>Transplantation Proceedings</i> , 2001, 33, 1634-1636.	0.3	25
76	Right Heart and Pulmonary Vessels Structure and Function. <i>Echocardiography</i> , 2015, 32, S3-10.	0.3	25
77	Effects of Glucose-Insulin-Potassium Infusion on Myocardial Perfusion and Left Ventricular Remodeling in Patients Treated With Primary Angioplasty for ST-Elevation Acute Myocardial Infarction. <i>American Journal of Cardiology</i> , 2006, 98, 1349-1353.	0.7	24
78	Hemodynamics and risk assessment 2 years after the initiation of upfront ambrisentan+tadalafil in pulmonary arterial hypertension. <i>Journal of Heart and Lung Transplantation</i> , 2020, 39, 1389-1397.	0.3	24
79	Pulmonary hypertension in systemic sclerosis: prevalence, incidence and predictive factors in a large multicentric Italian cohort. <i>Clinical and Experimental Rheumatology</i> , 2013, 31, 31-6.	0.4	24
80	Usefulness of Adding Echocardiography of the Right Heart to Risk-Assessment Scores in Prostanoid-Treated Pulmonary Arterial Hypertension. <i>JACC: Cardiovascular Imaging</i> , 2020, 13, 2054-2056.	2.3	23
81	Mid-Term Efficacy of Beraprost, an Oral Prostacyclin Analog, in the Treatment of Distal CTEPH: A Case Control Study. <i>Cardiology</i> , 2006, 106, 168-173.	0.6	21
82	Pulmonary Hypertension in Adults with Congenital Heart Disease: Real-World Data from the International COMPERA-CHD Registry. <i>Journal of Clinical Medicine</i> , 2020, 9, 1456.	1.0	21
83	Demographics, clinical characteristics, health resource utilization and cost of chronic thromboembolic pulmonary hypertension patients: retrospective results from six European countries. <i>BMC Health Services Research</i> , 2014, 14, 246.	0.9	20
84	Safety and efficacy evaluation of ambrisentan in pulmonary hypertension. <i>Expert Opinion on Drug Safety</i> , 2012, 11, 1003-1011.	1.0	19
85	Myocardial and microvascular inflammation/infection in patients with HIV-associated pulmonary artery hypertension. <i>Aids</i> , 2014, 28, 2541-2549.	1.0	18
86	Interleukin-32 in systemic sclerosis, a potential new biomarker for pulmonary arterial hypertension. <i>Arthritis Research and Therapy</i> , 2020, 22, 127.	1.6	18
87	Venous endothelin-1 (ET-1) and brain natriuretic peptide (BNP) plasma levels during 6-month bosentan treatment for pulmonary arterial hypertension. <i>Regulatory Peptides</i> , 2008, 151, 48-53.	1.9	17
88	Elevated serum levels of macrophage migration inhibitory factor and stem cell growth factor $\beta^2$ in patients with idiopathic and systemic sclerosis associated pulmonary arterial hypertension. <i>Reumatismo</i> , 2014, 66, 270-276.	0.4	17
89	Efficacy of 1, 5, and 20 mg oral sildenafil in the treatment of adults with pulmonary arterial hypertension: a randomized, double-blind study with open-label extension. <i>BMC Pulmonary Medicine</i> , 2017, 17, 44.	0.8	17
90	ISHLT consensus statement: Perioperative management of patients with pulmonary hypertension and right heart failure undergoing surgery. <i>Journal of Heart and Lung Transplantation</i> , 2022, 41, 1135-1194.	0.3	17

#	ARTICLE	IF	CITATIONS
91	Initial tadalafil and ambrisentan combination therapy in pulmonary arterial hypertension. <i>Journal of Cardiovascular Medicine</i> , 2018, 19, 12-17.	0.6	16
92	Timing and Priorities for Cystic Fibrosis Patients Candidates to Lung Transplantation. <i>European Journal of Pediatric Surgery</i> , 1998, 8, 274-277.	0.7	14
93	Heart failure in patients with human immunodeficiency virus. <i>Journal of Cardiovascular Medicine</i> , 2015, 16, 383-389.	0.6	14
94	The impact of delayed treatment on 6-minute walk distance test in patients with pulmonary arterial hypertension: A meta-analysis. <i>International Journal of Cardiology</i> , 2018, 254, 299-301.	0.8	14
95	Ambrisentan for the treatment of adults with pulmonary arterial hypertension: a review. <i>Current Medical Research and Opinion</i> , 2015, 31, 1793-1807.	0.9	13
96	The Growing Role of Echocardiography in Pulmonary Arterial Hypertension Risk Stratification: The Missing Piece. <i>Journal of Clinical Medicine</i> , 2021, 10, 619.	1.0	13
97	Riociguat treatment in patients with pulmonary arterial hypertension: Final safety data from the EXPERT registry. <i>Respiratory Medicine</i> , 2021, 177, 106241.	1.3	13
98	Human herpesvirus 8 and pulmonary hypertension. <i>Emerging Infectious Diseases</i> , 2005, 11, 1480-2.	2.0	13
99	Incremental value of cardiopulmonary exercise testing in intermediate-risk pulmonary arterial hypertension. <i>Journal of Heart and Lung Transplantation</i> , 2022, 41, 780-790.	0.3	13
100	Relationship between baseline ET-1 plasma levels and outcome in patients with idiopathic pulmonary hypertension treated with bosentan. <i>International Journal of Cardiology</i> , 2013, 167, 220-224.	0.8	12
101	Clinical impact of echocardiography in prognostic stratification after acute myocardial infarction. <i>American Journal of Cardiology</i> , 1998, 81, 17G-20G.	0.7	10
102	Prognostic significance of the echocardiographic estimate of pulmonary hypertension and of right ventricular dysfunction in acute decompensated heart failure. A pilot study in HFrefEF patients. <i>International Journal of Cardiology</i> , 2018, 271, 301-305.	0.8	10
103	Hemodynamics during inhaled nitric oxide in lung transplant candidates. <i>Transplantation Proceedings</i> , 1997, 29, 3367-3370.	0.3	9
104	Improved results with lung transplantation for cystic fibrosis. <i>Transplantation Proceedings</i> , 2001, 33, 1632-1633.	0.3	9
105	ECMO Assistance during Mechanical Ventilation: Effects Induced on Energetic and Haemodynamic Variables. <i>Computer Methods and Programs in Biomedicine</i> , 2021, 202, 106003.	2.6	9
106	Prognostic value of improvement endpoints in pulmonary arterial hypertension trials: A COMPERA analysis. <i>Journal of Heart and Lung Transplantation</i> , 2022, 41, 971-981.	0.3	9
107	Imaging risk in pulmonary arterial hypertension. <i>European Respiratory Journal</i> , 2020, 56, 2002313.	3.1	8
108	Medical treatment of pulmonary hypertension in adults with congenital heart disease: updated and extended results from the International COMPERA-CHD Registry. <i>Cardiovascular Diagnosis and Therapy</i> , 2021, 11, 1255-1268.	0.7	8

#	ARTICLE	IF	CITATIONS
109	The paradox of pulmonary arterial hypertension in Italy in the COVID-19 era: is risk of disease progression around the corner?. <i>European Respiratory Journal</i> , 2022, 60, 2102276.	3.1	8
110	â€œReal-lifeâ€™ information on pulmonary arterial hypertension: the iPHnet Project. <i>Current Medical Research and Opinion</i> , 2014, 30, 2409-2414.	0.9	7
111	Endogenous opioid system modulation in anginal pain: Demonstration of its central activity. <i>American Heart Journal</i> , 1992, 124, 589-595.	1.2	6
112	Intra-aortic balloon counterpulsation timing: A new numerical model for programming and training in the clinical environment.. <i>Computer Methods and Programs in Biomedicine</i> , 2020, 194, 105537.	2.6	6
113	Response to Letters Regarding Article, â€œAnticoagulation and Survival in Pulmonary Arterial Hypertension: Results From the Comparative, Prospective Registry of Newly Initiated Therapies for Pulmonary Hypertension (COMPERA)â€. <i>Circulation</i> , 2014, 130, e110-2.	1.6	5
114	Identification of coronary artery by-pass grafts: reliability of MRI in clinical practice. <i>International Journal of Cardiovascular Imaging</i> , 1992, 8, 85-94.	0.2	4
115	Usefulness of 2D echo Doppler in the preoperative assessment of cystic fibrosis patients who are candidates for lung transplantation. <i>Transplantation Proceedings</i> , 2001, 33, 1628-1629.	0.3	4
116	Choosing the best first line oral drug agent in patients with pulmonary hypertension: Evidence from a network meta-analysis. <i>International Journal of Cardiology</i> , 2013, 168, 4336-4338.	0.8	4
117	The importance of right ventricular function in patients with pulmonary arterial hypertension. <i>Expert Review of Respiratory Medicine</i> , 2018, 12, 809-815.	1.0	4
118	Pulmonary hypertension due to lung disease â€œ Results from COMPERA. , 2015, , .		4
119	Optimal duration of dual anti-platelet therapy after percutaneous coronary intervention. <i>Journal of Cardiovascular Medicine</i> , 2017, 18, 1-9.	0.6	3
120	Pulmonary hypertension in left heart disease: The need to continue to explore. <i>International Journal of Cardiology</i> , 2019, 288, 132-134.	0.8	3
121	Future perspective in diabetic patients with pre- and post-capillary pulmonary hypertension. <i>Heart Failure Reviews</i> , 2023, 28, 745-755.	1.7	3
122	Plasma adrenomedullin and endothelin-1 concentration during low-dose dobutamine infusion: Relationship between pulmonary uptake and pulmonary vascular pressure/flow characteristics. <i>Regulatory Peptides</i> , 2006, 136, 85-91.	1.9	2
123	SPHERIC-1 (Sildenafil and Pulmonary HypERTension in COPD): Intention-to-Treat (ITT) Analysis of Safety and Efficacy Data. <i>Journal of Heart and Lung Transplantation</i> , 2014, 33, S148-S149.	0.3	2
124	Riociguat in Combination With Prostacyclin Analogs for the Treatment of Pulmonary Arterial Hypertension (PAH): A Subgroup Analysis of the PATENT Studies. <i>Chest</i> , 2015, 148, 922A.	0.4	2
125	Switching from PDE5i to Riociguat in the RESPITE Study: Effect on Right Heart Function. <i>Journal of Heart and Lung Transplantation</i> , 2018, 37, S152.	0.3	2
126	Exercise energy expenditure in patients with idiopathic pulmonary arterial hypertension: Impact on clinical severity and survival. <i>Respiratory Physiology and Neurobiology</i> , 2019, 264, 33-39.	0.7	2



#	ARTICLE	IF	CITATIONS
127	Hemodynamic Evaluation of the Right Heart-Pulmonary Circulation Unit in Patients Candidate to Transjugular Intrahepatic Portosystemic Shunt. <i>Journal of Clinical Medicine</i> , 2022, 11, 461.	1.0	2
128	Computational Simulator Models and Invasive Hemodynamic Monitoring as Tools for Precision Medicine in Pulmonary Arterial Hypertension. <i>Journal of Clinical Medicine</i> , 2022, 11, 82.	1.0	2
129	Comment on TopyÅ,a-Putowska et al. Echocardiography in Pulmonary Arterial Hypertension: Comprehensive Evaluation and Technical Considerations. <i>J. Clin. Med.</i> 2021, 10, 3229. <i>Journal of Clinical Medicine</i> , 2022, 11, 3337.	1.0	2
130	Telehealth: A winning weapon to face the COVID-19 outbreak for patients with pulmonary arterial hypertension. <i>Vascular Pharmacology</i> , 2022, 145, 107024.	1.0	2
131	Efficacy of Amlodipine in the Treatment of Stable Effort Angina. <i>Clinical Drug Investigation</i> , 1997, 13, 108-112.	1.1	1
132	Tissue viability by contrast echocardiography. <i>European Journal of Echocardiography</i> , 2006, 7, S22-S29.	2.3	1
133	Unusual presentation for a patent ductus arteriosus. <i>European Respiratory Review</i> , 2009, 18, 174-176.	3.0	1
134	Mode of Death in Patients with Pulmonary Arterial Hypertension. <i>Journal of Heart and Lung Transplantation</i> , 2013, 32, S17-S18.	0.3	1
135	Right Ventricular Remodeling in Idiopathic Pulmonary Arterial Hypertension: Concentric Versus Eccentric Hypertrophy. <i>Journal of Heart and Lung Transplantation</i> , 2014, 33, S148.	0.3	1
136	FRIO445â€¦Efficacy and Safety of Riociguat in Patients with Pulmonary Arterial Hypertension (PAH) Associated with Connective Tissue Disease (CTD): Results from Patent-1 and Patent-2. <i>Annals of the Rheumatic Diseases</i> , 2015, 74, 588.2-589.	0.5	1
137	Effects of Riociguat in Treatment-Naive vs Pretreated Patients With Pulmonary Arterial Hypertension: 2-Year Efficacy Results From the PATENT-2 Study. <i>Chest</i> , 2016, 150, 1162A.	0.4	1
138	Letter to the editor about the paper â€œRight ventricular dyssynchrony predicts clinical outcomes in patients with pulmonary hypertensionâ€•by Murata et al.. <i>International Journal of Cardiology</i> , 2017, 234, 128.	0.8	1
139	Oxygen supplementation for pulmonary arterial hypertension? Clues from the REVEAL registry. <i>Journal of Heart and Lung Transplantation</i> , 2018, 37, 941-942.	0.3	1
140	Longâ€•term study of oral treprostinil to treat pulmonary arterial hypertension: dosing, tolerability, and pharmacokinetics. <i>Pulmonary Circulation</i> , 2020, 10, 1-9.	0.8	1
141	Peripheral Arterial Stiffness in Acute Pulmonary Embolism and Pulmonary Hypertension at Short-Term Follow-Up. <i>Journal of Clinical Medicine</i> , 2021, 10, 3008.	1.0	1
142	Complex connections: A young man presenting with shortness of breath, hypoxemia, right lumbar pain and left limb swelling. <i>Echocardiography</i> , 2022, , .	0.3	1
143	198â€•f Intrapulmonary shunt assessment in pulmonary arterial hypertension. <i>European Heart Journal Supplements</i> , 2021, 23, .	0.0	1
144	BOSENTAN THERAPY IN PATIENTS WITH PULMONARY HYPERTENSION SECONDARY TO CONGENITAL HEART DISEASE (EISENMENGER PHYSIOLOGY). <i>Chest</i> , 2005, 128, 366S.	0.4	0

#	ARTICLE	IF	CITATIONS
145	ACUTE HEMODYNAMIC EFFECT OF SILDENAFIL IN COMPARISON WITH INHALED NITRIC OXIDE IN PATIENTS RECEIVING BOSENTAN THERAPY FOR PULMONARY ARTERIAL HYPERTENSION. <i>Chest</i> , 2007, 132, 488A.	0.4	0
146	258: Predictors of Clinical Worsening in Patients with PAH Treated with Bosentan. <i>Journal of Heart and Lung Transplantation</i> , 2009, 28, S156-S157.	0.3	0
147	Right Ventricular Mass/diastolic Ratio: An Expression Of "adequate" RV Adaptation In Pulmonary Arterial Hypertension ?. , 2010, , .		0
148	Outcome Of Pregnancies In Women With Pulmonary Arterial Hypertension In The Modern Management Era. , 2011, , .		0
149	A Health Economic Analysis Of Sitaxentan For The Treatment Of Pulmonary Arterial Hypertension In Europe. , 2011, , .		0
150	PCV22 Treatment Patterns and Outcomes in Patients with Pulmonary Arterial Hypertension and Chronic Thromboembolic Pulmonary Hypertension: Results of a Retrospective Chart Review in Six European Countries. <i>Value in Health</i> , 2012, 15, A115.	0.1	0
151	Right Ventricular Dyssynchrony Predicts Clinical Worsening in Idiopathic Pulmonary Arterial Hypertension. <i>Journal of Heart and Lung Transplantation</i> , 2013, 32, S79.	0.3	0
152	Myocardial and micro-vascular inflammation/infection in HIV/HCV associated pulmonary artery hypertension. <i>European Heart Journal</i> , 2013, 34, P228-P228.	1.0	0
153	Right Ventricular Dyssynchrony in Idiopathic Pulmonary Arterial Hypertension: Insights From Echocardiographic and Cardiac Magnetic Resonance Imaging. <i>Journal of Heart and Lung Transplantation</i> , 2014, 33, S229.	0.3	0
154	Concentric Hypertrophy Protects Against Clinical Worsening in Idiopathic Pulmonary Arterial Hypertension: Insights From Magnetic Resonance Imaging. <i>Journal of Heart and Lung Transplantation</i> , 2015, 34, S117.	0.3	0
155	Determinants and Prognostic Significance of Right Ventricular Reverse Remodeling in Idiopathic Pulmonary Arterial Hypertension Receiving Specific Medical Treatment. <i>Journal of Heart and Lung Transplantation</i> , 2015, 34, S116-S117.	0.3	0
156	Muscular Efficiency in Patients With Idiopathic Pulmonary Arterial Hypertension (iPAH): Impact on Clinical Severity and Survival. <i>Journal of Heart and Lung Transplantation</i> , 2015, 34, S339.	0.3	0
157	Right Ventricular Dyssynchrony and Exercise Capacity in Idiopathic Pulmonary Arterial Hypertension: Insights Form Echocardiography and Cardiopulmonary Exercise Test. <i>Journal of Heart and Lung Transplantation</i> , 2016, 35, S149.	0.3	0
158	Incremental Benefit of Echocardiographic Imaging and Cardiopulmonary Exercise Test in Prognostic Evaluation of Idiopathic Pulmonary Arterial Hypertension. <i>Journal of Heart and Lung Transplantation</i> , 2016, 35, S149.	0.3	0
159	Incremental Benefit of Cardiopulmonary Exercise Testing for the Prediction of Outcome in Stable Prevalent Pulmonary Arterial Hypertension Patients. <i>Journal of Heart and Lung Transplantation</i> , 2017, 36, S76.	0.3	0
160	Echocardiography Predicts the Outcome in Pulmonary Arterial Hypertension Patients Treated With Parenteral Prostanoids. <i>Journal of Heart and Lung Transplantation</i> , 2018, 37, S206.	0.3	0
161	Initial combination therapy for patients with pulmonary arterial hypertension (PAH): a budget impact analysis from the perspective of the Italian national healthcare system. <i>Expert Opinion on Orphan Drugs</i> , 2018, 6, 1-7.	0.5	0
162	Clinical Impact of Right Ventricular Diastolic Patterns in Idiopathic Pulmonary Arterial Hypertension by Speckle Tracking. <i>Journal of Heart and Lung Transplantation</i> , 2019, 38, S487.	0.3	0

#	ARTICLE	IF	CITATIONS
163	Clinical Implications of Idiopathic Pulmonary Arterial Hypertension Phenotypes Defined by Cluster Analysis. <i>Journal of Heart and Lung Transplantation</i> , 2019, 38, S488.	0.3	0
164	Suppressor of Tumorigenicity 2 as a Biomarker in Pulmonary Arterial Hypertension and its Association with REVEAL Risk Score in Riociguat-Treated Patients in the RESPITE Study. <i>Journal of Heart and Lung Transplantation</i> , 2019, 38, S96.	0.3	0
165	Bayesian Network Modeling: The Future of Pulmonary Arterial Hypertension Risk Stratification Through the PHORA Initiative. , 2020, , .		0
166	An Analysis of FREEDOM-EV Using the French Noninvasive and Reveal 2.0 Risk Stratification Criteria. , 2020, , .		0
167	Reply to Weatherald et al.: Pulmonary Vascular Resistance in Pulmonary Arterial Hypertension: La Pi�ce de R�sistance?. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2021, 203, 525-526.	2.5	0
168	Right-Heart Reverse Remodeling During Treatment for Pulmonary Hypertension. , 2021, , 291-299.		0
169	Right ventricular assessment matters for precision medicine. Reply to �ldentifying parameters associated with response to switching from a PDE5i to riociguat in RESPITE�. <i>International Journal of Cardiology</i> , 2021, 333, 210.	0.8	0
170	Incidence and long-term outcomes of pregnant women complicated with pulmonary arterial hypertension during different pregnancies: A prospective cohort study from China. <i>International Journal of Cardiology</i> , 2021, 332, 193-194.	0.8	0
171	The Authors Reply. <i>JACC: Cardiovascular Imaging</i> , 2021, 14, 1488-1489.	2.3	0
172	P3391 Plasmatic cytokines in portopulmonary hypertension. <i>European Heart Journal</i> , 2003, 24, 652.	1.0	0
173	Human Herpesvirus 8 and Pulmonary Hypertension. <i>Emerging Infectious Diseases</i> , 2005, 12, 1480-1482.	2.0	0
174	BASELINE VENOUS ENDOTHELIN-1 (ET1) PLASMA LEVELS DOES NOT PREDICT CLINICAL RESPONSE TO BOSENTAN IN PULMONARY ARTERIAL HYPERTENSION. <i>Chest</i> , 2005, 128, 202S.	0.4	0
175	Ambrisentan and tadalafil as initial combination therapy for pulmonary arterial hypertension: clinical effect and haemodynamic changes. <i>An Italian multicenter retrospective analysis.</i> , 2017, , .		0
176	Early improvements predict outcomes in pulmonary arterial hypertension. , 2018, , .		0
177	SAT0296�...SERUM LEPTIN LEVELS IN SYSTEMIC SCLEROSIS PATIENTS WITH ELECTROCARDIOGRAPHIC ABNORMALITIES. <i>Annals of the Rheumatic Diseases</i> , 2020, 79, 1093.1-1093.	0.5	0
178	Switching from PDE5i to riociguat in patients with PAH: A responder analysis from REPLACE. , 2021, , .		0
179	150�f Incremental value of cardiopulmonary exercise testing in intermediate-risk pulmonary arterial hypertension. <i>European Heart Journal Supplements</i> , 2021, 23, .	0.0	0
180	121�f Imaging of improved right ventricular function and risk status in pulmonary arterial hypertension. <i>European Heart Journal Supplements</i> , 2021, 23, .	0.0	0

#	ARTICLE	IF	CITATIONS
181	Gaps of evidence in pulmonary arterial hypertension. International Journal of Cardiology, 2022, , .	0.8	0